Latest Lead News

Genesis Minerals delivered record gold production and a robust cash build in December 2025, while accelerating development at its Tower Hill project ahead of schedule.

Critical Resources Limited has secured a $1.75 million placement at market price, reinforcing investor confidence as it advances lithium, gold-antimony, and solid-state battery initiatives.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

Genesis Minerals has restructured its executive team, appointing Raleigh Finlayson as Executive Chair and promoting Matthew Nixon to CEO, positioning the company for a significant growth phase.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Silver Mines Limited has reported its best-ever drilling results at the Bowdens Silver Project in NSW while navigating a complex regulatory redetermination process. Exploration advances continue across its Australian and US projects, supported by a strong cash position.

Perpetual Limited’s second quarter FY26 update reveals a mixed performance with strong Corporate Trust growth balancing net outflows in Asset Management, while Wealth Management remains stable amid ongoing sale talks.

Temas Resources has confirmed its patented Regenerative Chloride Leach (RCL) technology can produce commercial-grade titanium dioxide with significant cost reductions, positioning the company for global licensing opportunities.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.